Sort   by:  
 Page size 
UnknownEffect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Not available
S-EPMC5057342 | biostudies-literature
UnknownHyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial.
Not available
S-EPMC8178474 | biostudies-literature
UnknownLong-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Not available
S-EPMC6073017 | biostudies-literature
UnknownHyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Not available
S-EPMC8763180 | biostudies-literature
UnknownFinerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Not available
S-EPMC8812430 | biostudies-literature
UnknownFinerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Not available
S-EPMC7864612 | biostudies-literature
UnknownEffect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
Not available
S-EPMC9799031 | biostudies-literature
UnknownModifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Not available
S-EPMC10267848 | biostudies-literature
UnknownBlood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
Not available
S-EPMC9640256 | biostudies-literature
UnknownEfficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
Not available
S-EPMC9293162 | biostudies-literature
Sort   by:  
 Page size